IO Biotech Provides Corporate Update

Core Viewpoint - IO Biotech is exploring strategic alternatives and has engaged Raymond James & Associates as its exclusive financial advisor [1][5] Group 1: Strategic Actions - The company is implementing cost-containment and cash conservation measures, which include a significant reduction in workforce to lower operating expenses during the exploration of strategic alternatives [2] Group 2: Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on developing novel immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win platform, which aims to activate T cells to target tumor cells and immune-suppressive cells in the tumor microenvironment [3]